Screener
Apogee Therapeutics, Inc. APGE Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Other income, net: | ||
| Interest income, net | 8,740 | 7,840 |
| Total other income, net | 8,740 | 7,840 |
| Net loss before taxes | (74,032) | (55,256) |
| Provision for income taxes | (79) | (83) |
| Net loss after taxes | $(74,111) | $(55,339) |
| Net loss per share, basic and diluted | $(1.06) | $(0.95) |
| Weighted-average common shares outstanding, basic and diluted | 69,668,439 | 58,195,272 |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s pre-tax income?
- Apogee Therapeutics, Inc. (APGE) reported pre-tax income of -$74.03M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s pre-tax income changed year-over-year?
- Apogee Therapeutics, Inc.'s pre-tax income decreased by 34.0% year-over-year, from -$55.26M to -$74.03M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s pre-tax income?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s pre-tax income has grown at a 74.4% compound annual growth rate (CAGR), from -$83.99M to -$255.57M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Apogee Therapeutics, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude